



**Un-audited Condensed Consolidated Interim Financial Statements of  
InMed Pharmaceuticals Inc.**

**For the Three Months Ended September 30, 2017**



**InMed Pharmaceuticals Inc.**  
(Expressed in Canadian Dollars)  
September 30, 2017

<b><u>INDEX</u></b>	<b><u>Page</u></b>
<b>Financial Statements</b>	
• Unaudited Condensed Consolidated Interim Statements of Financial Position	3
• Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss	4
• Unaudited Condensed Consolidated Interim Statements of Changes In Equity	5
• Unaudited Condensed Consolidated Interim Statements of Cash Flows	6
• Notes to the Consolidated Financial Statements	7-24

**InMed Pharmaceuticals Inc.**

**CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (un-audited)**

As at September 30, 2017 and June 30, 2017

Expressed in Canadian Dollars

	Note	September 30 2017	June 30 2017
<b>ASSETS</b>			
Current			
Cash and cash equivalents	4	\$ 6,032,762	\$ 6,707,796
Taxes recoverable and other receivables	5	23,968	59,148
Prepays and advances		136,634	177,577
<b>Total current assets</b>		<b>6,193,364</b>	<b>6,944,521</b>
Non-Current			
Property and equipment	6	50,387	27,049
Intangible assets	7	1,341,649	1,364,558
<b>Total Assets</b>		<b>\$ 7,585,400</b>	<b>\$ 8,336,128</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>			
Current			
Trade and other payables	8	189,551	369,674
<b>SHAREHOLDERS' EQUITY</b>			
Share capital	9, 13	44,047,455	43,153,871
Contributed surplus	9, 10	7,962,700	7,606,735
Accumulated deficit		(44,614,306)	(42,794,152)
		7,395,849	7,966,454
		<b>\$ 7,585,400</b>	<b>\$ 8,336,128</b>

Commitments (Note 18)

Approved on behalf of the Board of Directors by:

/s/ Eric A. Adams  
Eric A. Adams, Director

/s/ Adam Cutler  
Adam Cutler, Director

**InMed Pharmaceuticals Inc.****CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS (un-audited)**

For the three months ended September 30, 2017 and September 30, 2016

Expressed in Canadian Dollars

	Note	2017	2016
<b>Expenses</b>			
General and administrative	11, 13	\$ 841,340	\$ 130,530
Research and development	12	377,116	23,481
Amortization and depreciation	6, 7	26,626	22,529
Foreign exchange (gain) loss		4,524	(2,473)
Share-based payments	10	570,548	243,949
<b>Total expenses</b>		<b>1,820,154</b>	<b>418,016</b>
<b>Loss before other items</b>		<b>(1,820,154)</b>	<b>(418,016)</b>
<b>Total comprehensive loss for the year</b>		<b>\$ (1,820,154)</b>	<b>\$ (418,016)</b>
<b>Basic and diluted loss per share for the year</b>	14	<b>\$ (0.02)</b>	<b>\$ (0.01)</b>

**InMed Pharmaceuticals Inc.**

**CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY (un-audited)**

For the three months ended September 30, 2017 and September 30, 2016

Expressed in Canadian Dollars

	Note	Share Capital	Obligation to issue Shares	Shares Subscribed	Contributed Surplus	Accumulated Deficit	Total
<b>Balance June 30, 2016</b>		<b>\$32,777,875</b>	<b>\$70,000</b>	<b>\$131,400</b>	<b>\$6,402,550</b>	<b>(\$38,320,303)</b>	<b>\$1,061,522</b>
Loss for the period		-	-	-	-	(418,016)	(418,016)
Shares subscribed		-	-	160,000	-	-	160,000
Share-based payments	10	-	-	-	243,949	-	243,949
Shares for debt	9	108,169	-	-	-	-	108,169
Shares issued for cash	9	304,500	-	(131,400)	-	-	173,100
Fair value of agents warrants	9	-	-	-	527	-	527
Share issue costs	9	(3,233)	-	-	-	-	(3,233)
<b>Balance September 30, 2016</b>		<b>\$33,187,311</b>	<b>\$70,000</b>	<b>\$160,000</b>	<b>\$6,647,026</b>	<b>(\$38,738,319)</b>	<b>\$1,326,017</b>

	Note	Share Capital	Obligation to issue Shares	Shares Subscribed	Contributed Surplus	Accumulated Deficit	Total
<b>Balance June 30, 2017</b>		<b>\$43,153,871</b>	<b>\$0</b>	<b>\$0</b>	<b>\$7,606,735</b>	<b>(\$42,794,152)</b>	<b>\$7,966,454</b>
Loss for the period		-	-	-	-	(1,820,154)	(1,820,154)
Share-based payments	10	-	-	-	570,548	-	570,548
Shares issued on exercise of warrants	9	456,000	-	-	-	-	456,000
Shares issued on exercise of stock options	10	437,584	-	-	(214,584)	-	223,000
<b>Balance September 30, 2017</b>		<b>\$44,047,455</b>	<b>\$0</b>	<b>\$0</b>	<b>\$7,962,700</b>	<b>(\$44,614,306)</b>	<b>\$7,395,849</b>

**InMed Pharmaceuticals Inc.****CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (un-audited)**

For the three months ended September 30, 2017 and September 30, 2016

Expressed in Canadian Dollars

	Note	2017	2016
<b>OPERATING ACTIVITIES</b>			
<b>Cash flows from operating activities</b>			
Loss for the period		\$ (1,820,154)	\$ (418,016)
Adjustments to reconcile loss to net cash used in operating activities			
Amortization and depreciation	6, 7	26,626	22,529
Share-based payments	10	570,548	243,949
Changes in non-cash working capital balances:			
Prepays and advances		40,943	40,330
Taxes recoverable		35,180	(38,535)
Trade payables	8, 9, 17	(202,750)	(67,168)
<b>Total cash outflows from operating activities</b>		<b>(1,349,607)</b>	<b>(216,911)</b>
<b>Cash Flows From Investing Activities</b>			
Purchase of equipment	6, 17	(4,428)	-
<b>Total cash outflows from investing activities</b>		<b>(4,428)</b>	<b>-</b>
<b>Cash Flows From Financing Activities</b>			
Subscriptions received		-	160,000
Shares issued for cash	9	679,000	173,100
Share issue costs	9	-	(2,705)
<b>Cash provided by financing activities</b>		<b>679,000</b>	<b>330,395</b>
Increase (decrease) in cash during the period		(675,034)	113,484
<b>Cash and cash equivalents beginning of the period</b>		<b>6,707,796</b>	<b>54,241</b>
<b>Cash and cash equivalents end of the period</b>		<b>\$ 6,032,762</b>	<b>\$ 167,724</b>

See note 17 for Non-Cash Transactions

**INMED PHARMACEUTICALS INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

**FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016**

**(Expressed in Canadian Dollars)**

---

**1. CORPORATION INFORMATION**

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) was incorporated in the Province of British Columbia on May 19, 1981 under the *Business Corporations Act* of British Columbia.

The Company’s shares are listed on the Canadian Securities Exchange (“CSE” or “Exchange”) under the trading symbol “IN”, and under the trading symbol “IMLFF” on the OTCQB.

InMed is a pre-clinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems.

InMed’s corporate office and principal place of business is located at #340 – 200 Granville Street, Vancouver, B.C., Canada, V6C 1S4.

**2. BASIS OF PREPARATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

These condensed consolidated interim financial statements for the three month period ended September 30, 2017 have been prepared in accordance with IAS 34 Interim Financial Reporting. They do not include all disclosures that would otherwise be required in a complete set of financial statements and should be read in conjunction with the Company’s June 30, 2017 annual financial statements which have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and Interpretations of the International Financial Reporting Interpretations Committee.

These condensed consolidated interim financial statements have been prepared using accounting policies consistent with those used in the Company’s 2017 annual financial statements except for new standards, interpretations and amendments mandatorily effective for the first time from July 1, 2017 and income tax expense which is expected for the full financial year.

These condensed consolidated interim financial statements were authorized for issue by the Board of Directors on November 20, 2017.

These condensed consolidated interim financial statements have been prepared on the historical cost basis as modified by the revaluation of available-for-sale financial assets when applicable.

These condensed consolidated interim financial statements are presented in Canadian Dollars, which is also the Company’s functional currency.

The preparation of financial statements in compliance with IFRS requires management to make certain critical accounting estimates. It also requires management to exercise judgment in applying the Company’s accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 3.

**Basis of Consolidation**

These consolidated financial statements include the accounts of the inactive subsidiaries: Biogen Sciences Inc. (“BSI”), Meridex Network Corporation, Savicon Inc., Meridex USA and Sweetnam Consulting Inc.

## **2. BASIS OF PREPARATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont'd)**

### **Basis of Consolidation (cont'd)**

A subsidiary is an entity that the Company controls, either directly or indirectly, where control is defined as the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. All inter-company transactions and balances including unrealized income and expenses arising from intercompany transactions are eliminated in preparing consolidated financial statements.

### **Continuing Operations**

These consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will be able to meet its commitments, realize its assets and discharge its liabilities. The Company has a history of operating losses and negative cash flows from operations. The Company's ability to continue its operations on a going concern basis is dependent upon receiving continued support from its suppliers, its ability to raise additional financing through issuing equity or debt, and ultimately achieving profitable operations. There is no assurance that the Company will be successful in these efforts. These consolidated financial statements do not reflect adjustments to the carrying values of assets and liabilities that would be necessary if the Company was unable to continue as a going concern and such adjustments could be material.

### **Future Accounting Pronouncements**

The standards listed below include only those which the Company reasonably expects may be applicable to the Company at a future date. The Company is currently assessing the impact of the standards on the consolidated financial statements.

#### **IFRS 9 Financial Instruments**

Issued by IASB July, 2014

Effective for annual periods beginning on or after January 1, 2018

IFRS 9 will replace IAS 39 Financial Instruments: Recognition and Measurement and IFRIC 9 Reassessment of Embedded Derivatives. The main features introduced by this new standard compared with predecessor IFRS are as follows:

- *Classification and measurement of financial assets:*  
Debt instruments are classified and measured on the basis of the entity's business model for managing the asset and its contractual cash flow characteristics as either: "amortized cost", "fair value through other comprehensive income", or "fair value through profit or loss" (default). Equity instruments are classified and measured as "fair value through profit or loss" unless upon initial recognition elected to be classified as "fair value through other comprehensive income".
- *Classification and measurement of financial liabilities:*  
When an entity elects to measure a financial liability at fair value, gains or losses due to changes in the entity's own credit risk is recognized in other comprehensive income (as opposed to previously profit or loss). This change may be adopted early in isolation of the remainder of IFRS 9.



## **2. BASIS OF PREPARATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont'd)**

### **Future Accounting Pronouncements (cont'd)**

#### **IFRS 9 Financial Instruments (cont'd)**

- ***Impairment of financial assets:***  
An expected credit loss impairment model replaced the incurred loss model and is applied to financial assets at “amortized cost” or “fair value through other comprehensive income”, lease receivables, contract assets or loan commitments and financial guarantee contracts. An entity recognizes twelve-month expected credit losses if the credit risk of a financial instrument has not increased significantly since initial recognition and lifetime expected credit losses otherwise.
- ***Hedge accounting:***  
Hedge accounting remains a choice, however, is now available for a broader range of hedging strategies. Voluntary termination of a hedging relationship is no longer permitted. Effectiveness testing now needs to be performed prospectively only. Entities may elect to continue to applying IAS 39 hedge accounting on adoption of IFRS 9 (until the IASB has completed its separate project on the accounting for open portfolios and macro hedging).
- ***Derecognition:***  
The requirements for the derecognition of financial assets and liabilities are carried forward from IAS 39.

#### **IFRS 16 Leases**

Issued by IASB January, 2016

Effective for annual periods beginning on or after January 1, 2019

Earlier application permitted for entities that also apply IFRS 15 Revenue from Contracts with Customers.

This new standard sets out the principles for the recognition, measurement, presentation and disclosure of leases for both the lessee and the lessor. The new standard introduces a single lessee accounting model that requires the recognition of all assets and liabilities arising from a lease.

The main features of the new standard are as follows:

- An entity identifies as a lease a contract that conveys the right to control the use of an identified asset for a period of time in exchange for consideration.
- A lessee recognizes an asset representing the right to use the leased asset, and a liability for its obligation to make lease payments. Exceptions are permitted for short-term leases and leases of low-value assets.
- A lease asset is initially measured at cost, and is then depreciated similarly to property, plant and equipment. A lease liability is initially measured at the present value of the unpaid lease payments.
- A lessee presents interest expense on a lease liability separately from depreciation of a lease asset in the statement of profit or loss and other comprehensive income.
- A lessor continues to classify its leases as operating leases or finance leases, and to account for them accordingly.
- A lessor provides enhanced disclosures about its risk exposure, particularly exposure to residual-value risk.

The new standard supersedes the requirements in IAS 17 Leases, IFRIC 4 Determining whether an Arrangement contains a Lease, SIC-15 Operating Leases – Incentives, and SIC-27 Evaluating the Substance of Transactions Involving the Legal Form of a Lease.

### **3. SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS**

The Company makes estimates and assumptions about the future that affect the reported amounts of assets and liabilities. Estimates and judgments are continually evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. In the future, actual experience may differ from these estimates and assumptions.

The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income (loss) in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both.

Information about critical judgments in applying accounting policies that have the most significant risk of causing material adjustment to the carrying amounts of assets and liabilities recognized in the financial statements within the next financial period are discussed below:

#### Estimate of useful life of intangible assets

In the determination of the estimated useful life for intangible assets, which include the Company's Bioinformatics Assessment Tool and certain patents, management assesses a variety of internal and external factors such as the expected usage of the intangible assets by the Company, technical or commercial obsolescence and expected actions by competitors or potential competitors.

#### Application of going concern assumption

The assessment of whether the going concern assumption is appropriate requires management to take into account all available information about the future, which is at least, but is not limited to, 12 months from the end of the reporting period.

#### Assets' impairment

In the determination of potential impairment charges, management looks at the higher of recoverable amount or fair value less costs to sell in the case of assets and at significant or prolonged decline of fair value on financial assets indicating impairment. These determinations and their individual assumptions require that management make a decision based on the best available information at each reporting period.

#### Share-based payments and warrants

Management determines costs for share-based payments and warrants using market-based valuation techniques. The fair value of the market-based and performance-based share awards are determined at the date of grant using generally accepted valuation techniques. Assumptions are made and judgment used in applying valuation techniques. These assumptions and judgments include estimating the future volatility of the stock price, expected dividend yield, future employee turnover rates and future employee stock option exercise behaviors and corporate performance. Such judgments and assumptions are inherently uncertain. Changes in these assumptions affect the fair value estimates.

### **4. CASH**

Cash consists of cash at banks and earns interest at floating and fixed rates based on daily deposit rates. Cash equivalents of \$28,750 (June 30, 2017: \$28,750) is held in a guaranteed investment certificate that is pledged as security for a corporate credit card.

**INMED PHARMACEUTICALS INC.****NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(Expressed in Canadian Dollars)

**5. RECEIVABLES**

	September 30 2017	June 30 2017
Taxes recoverable	\$ 23,968	\$ 59,148
	\$ 23,968	\$ 59,148

Taxes recoverable represents input tax credits arising from sales tax levied on the supply of goods purchased or services received in Canada.

Management considers that the fair values of these receivables, which are expected to be recovered quarterly, are not materially different from their carrying amounts because these amounts have short maturity periods on inception.

**6. PROPERTY AND EQUIPMENT**

	Equipment	Leasehold Improvements	Total
<b>Cost</b>			
Balance at June 30, 2016	\$ 9,330	\$ —	\$ 9,330
Assets acquired	25,393	—	25,393
Balance at June 30, 2017	\$ 34,723	\$ —	\$ 34,723
Assets acquired	3,734	23,321	27,055
Balance September 30, 2017	\$ 38,457	\$ 23,321	\$ 61,778
<b>Depreciation and impairment losses</b>			
Balance at June 30, 2016	\$ 4,604	\$ —	\$ 4,604
Depreciation for the period	3,070	—	3,070
Balance at June 30, 2017	\$ 7,674	\$ —	\$ 7,674
Depreciation for the period	2,745	972	3,717
Balance September 30, 2017	\$ 10,419	\$ 972	\$ 11,391
<b>Carrying amounts</b>			
Carrying value at June 30, 2017	\$ 27,049	\$ —	\$ 27,049
Carrying value at September 30, 2017	\$ 28,038	\$ 22,349	\$ 50,387

**INMED PHARMACEUTICALS INC.**  
**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016**  
(Expressed in Canadian Dollars)

---

**7. INTANGIBLE ASSETS**

	<b>Intellectual Property</b>
<b>Costs</b>	
Balance at June 30, 2016	\$1,636,000
Balance at June 30, 2017	\$1,636,000
<b>Balance at September 30, 2017</b>	<b>\$1,636,000</b>
<b>Accumulated amortization and impairment losses</b>	
Balance at June 30, 2016	\$176,689
Amortization	94,753
Balance at June 30, 2017	\$271,442
Amortization	22,909
<b>Balance at September 30, 2017</b>	<b>\$294,351</b>
<b>Carrying amounts</b>	
Carrying value at June 30, 2017	\$1,364,558
<b>Carrying value at September 30, 2017</b>	<b>\$1,341,649</b>

The acquired intellectual property, which consists of the Company's Bioinformatics Assessment Tool and certain patents, is recorded at cost and is amortized on a straight line basis over an estimated useful life of 18 years net of any accumulated impairment losses.

**Acquisitions**

On October 28, 2015, the Company entered into a purchase agreement with Dr. Sazzad Hossain, the Company's Chief Scientific Officer, to acquire certain patents from Dr. Hossain, in return for the obligation of the Company to issue 1,000,000 common shares to Dr. Hossain. The 1,000,000 common shares have an aggregate recorded value at \$140,000, or \$0.14 per share, as determined by the closing price of the shares on the CSE on October 28, 2015. As at June 30, 2016, 500,000 of such common shares had been issued to Dr. Hossain; accordingly, the Company had an obligation to issue a further 500,000 common shares valued at \$70,000 to Dr. Hossain under the terms of the purchase agreement between the parties dated October 28, 2015. These 500,000 common shares were issued on May 5, 2017 (Note 9).

On May 10, 2014, the Company entered into a Share Purchase Agreement ("SPA") to acquire Biogen Sciences Inc. ("BSI"), a privately held British Columbia biopharmaceutical company focused on drug discovery and development of the therapeutic science of cannabinoids.

On May 21, 2014, pursuant to the terms of the SPA the Company acquired 100% of the outstanding common shares of BSI. The aggregate purchase price included the issuance of 4,000,000 common shares of the Company to the vendors with a recorded value of \$1,360,000 (issue price of \$0.34, as determined by the closing price of the shares on the CSE on May 21, 2014) and the issuance of 400,000 common shares of the Company as finders' fees with a recorded value of \$136,000 (issue price of \$0.34, as determined by the closing price of the shares on the CSE on May 21, 2014).

The Company determined the acquisition of BSI did not meet the definition of a business pursuant to IFRS and accordingly the purchase has been accounted for as an asset acquisition, with the primary assets acquired being the intellectual property which includes the Bioinformatics Assessment Tool and a pending patent application. Pursuant to the completion of the acquisition, BSI became a wholly owned subsidiary of InMed.

**INMED PHARMACEUTICALS INC.**  
**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016**  
(Expressed in Canadian Dollars)

**8. TRADE PAYABLES**

	<b>September 30</b>		<b>June 30</b>	
	<b>2017</b>		<b>2017</b>	
Trade payables	\$	<b>189,551</b>	\$	<b>369,674</b>
<b>Total</b>	<b>\$</b>	<b>189,551</b>	<b>\$</b>	<b>369,674</b>

**9. SHARE CAPITAL AND RESERVES**

**a) Authorized**

As at September 30, 2017, the Company's authorized share structure consisted of: (i) an unlimited number of common shares without par value; and (ii) unlimited number of preferred shares without par value.

**b) Common Shares**

	<b>Number</b>	<b>Issue Price</b>	<b>Total</b>
Balance at June 30, 2016	68,232,862		\$32,777,875
Issued shares for debt	983,355	\$0.11	108,169
Issued for private placement	31,383,334	\$0.07 - \$0.18	3,295,500
Issued for public placement	12,788,000	\$0.45	5,754,599
Issued for intangible assets	500,000	\$0.14	70,000
Issued for services	641,165	\$0.17 - \$0.415	206,646
Issued for exercise of warrants	12,325,750	\$0.13 - \$0.30	1,678,458
Fair value of agents' warrants exercised	—	—	111,288
Issued for exercise of stock options	875,000	\$0.14 - \$0.345	152,625
Grant date fair value of stock options exercised	—	—	137,633
Cancellation of escrow shares	(80,000)	—	—
Share issue costs			<b>(1,138,922)</b>
Balance at June 30, 2017	127,649,466	—	\$43,153,871
Issued for exercise of warrants	3,040,000	\$0.15	456,000
Issued for exercise of stock options	1,200,000	\$0.14 - \$0.195	223,000
Grant date fair value of stock options exercised	—	—	214,584
<b>Balance at September 30, 2017</b>	<b>131,889,466</b>	<b>—</b>	<b>\$44,047,455</b>

During the three months ended September 30, 2017, the Company completed the following:

- i) The Company issued an aggregate 3,040,000 common shares pursuant to the exercise of share purchase warrants at a weighted average exercise price of \$0.15 per share.
- ii) The Company issued an aggregate 1,200,000 common shares pursuant to the exercise of stock options at a weighted average exercise price of \$0.19 per share.

During the year ended June 30, 2017, the Company completed the following:

- iii) On July 6, 2016, the Company issued an aggregate 983,355 common shares pursuant to the settlement of trade payable debt in the amount of \$108,169 at an issue price of \$0.11 per common share.

**9. SHARE CAPITAL AND RESERVES (cont'd)**

**b) Common Shares (cont'd)**

- iv) On July 28, 2016, the Company completed a non-brokered private placement ("July-2016 Financing") for 4,350,000 units ("Units"), at a price of \$0.07 per Unit for gross proceeds of \$304,500 (which includes subscriptions of \$131,400 received as at June 30, 2016). Each Unit consists of one common share and one non-transferable share purchase warrant (a "July-2016 Warrant"). Each July-2016 Warrant is exercisable by the holder to acquire one additional common share at a price of \$0.15 for a period of twelve (12) months expiring on July 28, 2017.

Finders' fees of 7.0% on a portion of the gross proceeds received by the Company from the sale of Units sold pursuant to the July-2016 Financing included cash of \$2,706, and 28,000 warrants ("July-2016 Agent Warrants"). Each July-2016 Agent Warrant is exercisable in whole or in part at an exercise price of \$0.15 for a period of 12 months expiring on July 28, 2017.

- v) On October 27, 2016, the Company completed a non-brokered private placement (the "October-2016 Financing") for 18,750,000 common shares, at a price of \$0.08 per share for gross proceeds of \$1,500,000.

Finders' fees of 7.5% on a portion of the gross proceeds received by the Company from the sale of Units sold pursuant to the October-16 Financing included cash of \$637, and 237,500 compensation shares valued at \$0.17 per share.

- vi) On January 18, 2017, the Company completed a non-brokered private placement (the "January-2017 Financing") for 8,283,334 common shares, at a price of \$0.18 per share for gross proceeds of \$1,491,000.

Finders' fees of 7.5% on a portion of the gross proceeds received by the Company from the sale of Units sold pursuant to the January-2017 Financing included cash of \$45,237, 153,665 compensation shares valued at \$0.415 per share, and 170,364 warrants ("January-2017 Agent Warrants"). Each January-2017 Agent Warrant is exercisable in whole or in part at an exercise price of \$0.18 for a period of 12 months expiring on January 18, 2018.

- vii) Pursuant to a February 21, 2017 agreement with a consultant to the Company, on March 1, 2017 the Company issued 250,000 common shares at a value of \$0.41 per common share, being the closing price of the shares on February 21, 2017 on the CSE, as partial payment for services.

- viii) On May 1, 2017, the Company cancelled and returned to treasury 80,000 common shares of the Company which had been held in escrow since February 9, 2000 pursuant to an escrow agreement between the Company, Montreal Trust Company of Canada (now part of Computershare Investor Services Inc.), and two shareholders. These 80,000 common shares were originally issued upon the closing of a reverse takeover transaction on February 9, 2000 as performance shares and were placed into escrow on closing. Under the terms of the Escrow Agreement, any such performance shares not released by February 9, 2010 were to be cancelled. As none of the performance criteria were achieved, none of these common shares were ever released from escrow prior to their cancellation on May 1, 2017.

- ix) On May 5, 2017, the Company issued the remaining 500,000 common shares, valued at \$70,000, due to the Company's Chief Scientific Officer, pursuant to an October 28, 2015 purchase agreement to acquire certain patents from Dr. Hossain.

**INMED PHARMACEUTICALS INC.**  
**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016**  
(Expressed in Canadian Dollars)

**9. SHARE CAPITAL AND RESERVES (cont'd)**

**b) Common Shares (cont'd)**

- x) On May 31, 2017, the Company completed a public placement (“May-2017 Financing”) of 12,788,000 units (“Units”), at a price of \$0.45 per Unit for gross proceeds of \$5,754,601. Each Unit consists of one common share and one-half non-transferable share purchase warrant (a “May-2017 Warrant”), or an aggregate of 6,394,000 full May-2017 Warrants. Each full May-2017 Warrant is exercisable by the holder to acquire one additional common share at a price of \$0.65 for a period of twenty-four (24) months expiring on May 31, 2019. The May-2017 Warrants are only exercisable on a net cashless basis, based on the five-day volume-weighted average trading price of the common shares of the Company on the CSE ending on the date immediately preceding the date of exercise.

Underwriters’ commissions of up to 7.0% on the gross proceeds received by the Company from the sale of Units sold pursuant to the May-2017 Financing included cash of \$370,132 and 535,620 warrants (“Agent Warrants”). Each Agent Warrant is exercisable in whole or in part at an exercise price of \$0.45 for a period of 12 months expiring on May 31, 2018.

- xi) During the year ending June 30, 2017, the Company issued an aggregate 12,325,750 common shares pursuant to the exercise of share purchase warrants at a weighted average exercise price of \$0.14 per share.
- xii) During the year ending June 30, 2017, the Company issued an aggregate 875,000 common shares pursuant to the exercise of stock options at a weighted average exercise price of \$0.17 per share.

**c) Share Purchase Warrants**

The following is a summary of changes in share purchase warrants from July 1, 2016 to September 30, 2017:

	Number	Weighted Average Share Price
Balance as at June 30, 2016	11,504,998	\$0.15
Granted	10,744,000	\$0.45
Exercised	(11,715,000)	\$0.14
Expired	(1,099,998)	\$0.30
Balance as at June 30, 2017	9,434,000	\$0.49
Exercised	(3,040,000)	\$0.15
<b>Balance as at September 30, 2017</b>	<b>6,394,000</b>	<b>\$0.65</b>

At September 30, 2017, 6,394,000 share purchase warrants were outstanding. Each warrant entitles the holders thereof the right to purchase one common share as follows:

	Number	Exercise Price	Expiry Date
	6,394,000	\$0.65	May 31-19
<b>Balance as at September 30, 2017</b>	<b>6,394,000</b>		

The weighted average remaining contractual life of the share purchase warrants at September 30, 2017 was 1.67 years.

**9. SHARE CAPITAL AND RESERVES (cont'd)**

**d) Agents Warrants**

The following is a summary of changes in agents' warrants from July 1, 2016 to September 30, 2017:

	Number	Weighted Average Share Price
Balance as at June 30, 2016	581,450	\$0.14
Granted	733,984	\$0.38
Expired	(610,750)	\$0.13
Exercised	(33,700)	\$0.29
Balance as at June 30, 2017	670,984	\$0.40
<b>Balance as at September 30, 2017</b>	<b>670,984</b>	<b>\$0.40</b>

At September 30, 2017, 670,984 Agent Warrants were outstanding. Each warrant entitles the holders thereof the right to purchase one common share as follows:

	Number	Exercise Price	Expiry Date
	135,364	\$0.18	January 18-18
	535,620	\$0.45	May 31-18
<b>Balance as at September 30, 2017</b>	<b>670,984</b>		

The weighted average remaining contractual life of the Agents' Warrants at September 30, 2017 was 0.59 years.

**e) Contributed Surplus**

Contributed surplus consists of the grant date fair value of stock options and agent warrants granted since inception, less amounts transferred to share capital for exercised stock options and agent warrants. If granted options vest and then subsequently expire or are forfeited, no reversal of contributed surplus is recognized.

**f) Nature and Purpose of Equity Reserves**

The reserves recorded in equity on the Company's Statement of Financial Position include 'Contributed Surplus' and 'Accumulated Deficit'.

'Contributed Surplus' is used to recognize the value of stock option grants and agents' warrants prior to exercise.

'Accumulated Deficit' is used to record the Company's change in deficit from earnings from year to year.



## **10. SHARE-BASED PAYMENTS**

### **a) Option Plan Details**

On March 24, 2017, the Company held a special meeting of its shareholders at which the Company's shareholders approved: (i) the adoption of a new stock option plan (the "Plan") pursuant to which the board of directors may, from time to time, in its discretion and in accordance with the requirements of the CSE, grant to directors, officers, employees and consultants of the Company, non-transferable options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed twenty percent (20%) of the issued and outstanding common shares at the date the options are granted (on a non-diluted and rolling basis); (ii) the application of the new stock option plan to all outstanding stock options of the Company that were granted prior to March 24, 2017 under the terms of the Company's previous stock option plan.

As at September 30, 2017, there was 8,627,893 (June 30, 2017 – 9,329,893) options available for future allocation. The option price under each option shall be not be less than the Discounted Market Price as defined in the policies of the Exchange on the Grant Date. All options vest upon terms as set by the Board of Directors. Starting in May 2016, the Board of Directors adopted a practice of having options vest over time, typically 18 to 24 months, and/or upon the achievement of certain corporate milestones.

**INMED PHARMACEUTICALS INC.**
**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**
**FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016**

(Expressed in Canadian Dollars)

**10. SHARE-BASED PAYMENTS (cont'd)**
**a) Option Plan Details (cont'd)**

The following is a summary of changes in options from July 1, 2017 to September 30, 2017:

Grant Date	Expiry Date	Exercise Price	Opening Balance	Granted	Exercised	Cancelled	Closing Balance	Vested and Exercisable	Unvested
4-Apr-14	4-Apr-19	\$0.255	250,000	-	-	-	250,000	250,000	-
5-Jun-14	5-Jun-19	\$0.18	50,000	-	-	-	50,000	50,000	-
31-Jul-14	31-Jul-19	\$0.18	50,000	-	-	-	50,000	50,000	-
25-Nov-14	25-Nov-19	\$0.180	50,000	-	-	-	50,000	50,000	-
2-Mar-15	2-Mar-20	\$0.345	150,000	-	-	-	150,000	150,000	-
4-Mar-15	4-Mar-20	\$0.360	200,000	-	-	-	200,000	200,000	-
25-Aug-15	25-Aug-20	\$0.210	150,000	-	-	-	150,000	150,000	-
23-Nov-15	23-Nov-20	\$0.145	200,000	-	-	-	200,000	200,000	-
27-Nov-15	27-Nov-20	\$0.140	1,300,000	-	(200,000)	-	1,100,000	1,100,000	-
16-May-16	16-May-21	\$0.080	2,000,000	-	-	-	2,000,000	1,100,000	900,000
10-Jun-16	10-Jun-21	\$0.130	1,000,000	-	-	-	1,000,000	600,000	400,000
15-Jun-16	15-Jun-21	\$0.110	2,000,000	-	-	-	2,000,000	2,000,000	-
26-Jul-16	26-Jul-21	\$0.11	1,750,000	-	-	-	1,750,000	1,400,000	350,000
12-Sep-16	12-Sep-21	\$0.11	1,000,000	-	-	-	1,000,000	600,000	400,000
28-Oct-16	28-Oct-21	\$0.195	2,700,000	-	(1,000,000)	-	1,700,000	900,000	800,000
15-Nov-16	15-Nov-21	\$0.165	750,000	-	-	-	750,000	250,000	500,000
12-Dec-16	12-Dec-21	\$0.14	300,000	-	-	-	300,000	100,000	200,000
13-Jan-17	13-Jan-22	\$0.25	1,000,000	-	-	-	1,000,000	400,000	600,000
20-Feb-17	20-Feb-22	\$0.37	100,000	-	-	-	100,000	40,000	60,000
22-Feb-17	22-Feb-22	\$0.41	50,000	-	-	-	50,000	50,000	-
2-Jun-17	2-Jun-22	\$0.45	1,150,000	-	-	-	1,150,000	25,000	1,125,000
15-Jul-17	15-Jul-22	\$0.33	-	400,000	-	-	400,000	-	400,000
14-Aug-17	14-Aug-22	\$0.275	-	1,350,000	-	-	1,350,000	750,000	600,000
12-Sep-17	12-Sep-22	\$0.425	-	1,000,000	-	-	1,000,000	-	1,000,000
			16,200,000	2,750,000	(1,200,000)	-	17,750,000	10,415,000	7,335,000
Weighted Average Exercise Price			\$0.17	\$0.34	\$0.19	-	\$0.20	\$0.16	\$0.26
Weighted Average Life remaining			4.04	4.89	-	-	3.92	3.63	4.32

**INMED PHARMACEUTICALS INC.**
**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**
**FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016**
**(Expressed in Canadian Dollars)**
**10. SHARE-BASED PAYMENTS (cont'd)**
**a) Option Plan Details (cont'd)**

The following is a summary of changes in options from July 1, 2016 to June 30, 2017:

Grant Date	Expiry Date	Exercise Price	Opening Balance	Granted	Exercised	Cancelled	Closing Balance	Vested and Exercisable	Unvested
4-Apr-14	4-Apr-19	\$0.255	375,000	-	(125,000)	-	250,000	250,000	-
5-Jun-14	5-Jun-19	\$0.18	50,000	-	-	-	50,000	50,000	-
31-Jul-14	31-Jul-19	\$0.18	50,000	-	-	-	50,000	50,000	-
25-Nov-14	25-Nov-19	\$0.180	100,000	-	(50,000)	-	50,000	50,000	-
2-Mar-15	2-Mar-20	\$0.345	200,000	-	(50,000)	-	150,000	150,000	-
4-Mar-15	4-Mar-20	\$0.360	200,000	-	-	-	200,000	200,000	-
15-Apr-15	15-Apr-20	\$0.295	2,400,000	-	-	(2,400,000)	-	-	-
25-May-15	25-May-20	\$0.235	400,000	-	-	(400,000)	-	-	-
25-Aug-15	25-Aug-20	\$0.210	200,000	-	(50,000)	-	150,000	150,000	-
23-Nov-15	23-Nov-20	\$0.145	200,000	-	-	-	200,000	200,000	-
27-Nov-15	27-Nov-20	\$0.140	1,900,000	-	(600,000)	-	1,300,000	1,300,000	-
16-May-16	16-May-21	\$0.080	2,000,000	-	-	-	2,000,000	1,100,000	900,000
10-Jun-16	10-Jun-21	\$0.130	1,000,000	-	-	-	1,000,000	600,000	400,000
15-Jun-16	15-Jun-21	\$0.110	2,000,000	-	-	-	2,000,000	2,000,000	-
26-Jul-16	26-Jul-21	\$0.11	-	1,750,000	-	-	1,750,000	1,200,000	550,000
12-Sep-16	12-Sep-21	\$0.11	-	1,000,000	-	-	1,000,000	400,000	600,000
28-Oct-16	28-Oct-21	\$0.195	-	2,700,000	-	-	2,700,000	1,900,000	800,000
15-Nov-16	15-Nov-21	\$0.165	-	750,000	-	-	750,000	250,000	500,000
12-Dec-16	12-Dec-21	\$0.14	-	300,000	-	-	300,000	100,000	200,000
13-Jan-17	13-Jan-22	\$0.25	-	1,000,000	-	-	1,000,000	200,000	800,000
20-Feb-17	20-Feb-22	\$0.37	-	100,000	-	-	100,000	20,000	80,000
22-Feb-17	22-Feb-22	\$0.41	-	50,000	-	-	50,000	50,000	-
2-Jun-17	2-Jun-22	\$0.45	-	1,150,000	-	-	1,150,000	25,000	1,125,000
			11,075,000	8,800,000	(875,000)	(2,800,000)	16,200,000	10,245,000	5,955,000
Weighted Average Exercise Price			\$0.17	\$0.21	\$0.17	\$0.29	\$0.17	\$0.15	\$0.21
Weighted Average Life remaining			4.38	4.38	-	-	4.04	3.86	4.35

**INMED PHARMACEUTICALS INC.**  
**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016**  
(Expressed in Canadian Dollars)

**10. SHARE-BASED PAYMENTS (cont'd)**

**b) Fair Value of Options Issued During the Period**

i) The weighted average fair value at grant date of options granted during the 3 month period ended September 30, 2017 was \$0.33 per option (year ending June 30, 2017 - \$0.16). Assumptions used for options granted during the year included a weighted average risk-free interest rate of 1.58% (year ending June 30, 2017 - 0.85%), weighted average expected life of 5 years (year ending June 30, 2017 - 5 years), weighted average volatility factor of 189.71% (year ending June 30, 2017 - 193.45%) and weighted average dividend yield of 0% (year ending June 30, 2017 - 0%) and a 5% forfeiture rate (year ending June 30, 2017 - 5%). The expected price volatility is based on historic volatility of the Company or companies of similar business and nature, based on the expected life of the options, adjusted for any expected changes to future volatility due to publicly available information.

ii) Expenses Arising from Share-based Payment Transactions

Total expenses arising from share-based payment transactions recognized during the 3 month period ended September 30, 2017 were \$570,548 (September 30, 2016 - \$243,949).

iii) Weighted average remaining contractual life of stock options

The weighted average remaining contractual life of stock options at September 30, 2017 was 3.92 years (June 30, 2017 - 4.04 years).

**11. ADMINISTRATIVE AND GENERAL EXPENSES**

	Three months ended September 30	
	2017	2016
<b>Administrative and General Expenses include:</b>		
Accounting and legal	\$ 60,615	\$ 12,125
Consulting	-	25,269
Corporate development	51,319	-
Investor relations, website development and marketing	512,169	36,967
Office and administration fees	49,572	6,992
Regulatory fees	14,877	4,854
Rent	16,543	2,971
Shareholder communication	3,474	5,643
Transfer agent fees	1,940	2,889
Travel	14,421	589
Salaries and employee benefits	116,410	32,231
	<b>\$ 841,340</b>	<b>\$ 130,530</b>

**12. RESEARCH AND DEVELOPEMENT EXPENSES**

	Three months ended September 30	
	2017	2016
<b>Research and Development Expenses include:</b>		
R&D personnel compensation	\$ 157,081	\$ 32,231
External contractors	128,083	(8,750)
Patents	48,934	-
Lab supplies	39,955	-
Other	3,063	-
	<b>\$ 377,116</b>	<b>\$ 23,481</b>

**INMED PHARMACEUTICALS INC.**  
**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016**  
(Expressed in Canadian Dollars)

**13. RELATED PARTY TRANSACTIONS**

**Payments**

Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain officers and senior consultants of the Company. The table below presents data for the 3 month period ending September 30, 2017 as compared to the same period ending September 30, 2016.

	September 30 2017	September 30 2016
Key management personnel compensation comprised :		
Share based payments	\$237,562	\$185,041
Salaries and consulting fees:	\$205,000	\$69,244
	<b>\$442,562</b>	<b>\$254,285</b>

- Salaries of \$70,000 (September 30, 2016 - \$30,000) were paid or accrued to Eric A. Adams, the Chief Executive Officer and President of the Company;
- Salaries of \$40,000 (September 30, 2016 - \$Nil) were paid or accrued to Jeff Charpentier ("Charpentier"), the Chief Financial Officer and Secretary of the Company (*Charpentier was appointed effective December 12, 2016*);
- Consulting fees of \$Nil (September 30, 2016 - \$9,244) were paid or accrued to Minco Corporate Management Inc. ("Minco") a company controlled by Terese Gieselman ("Gieselman"), the former Chief Financial Officer and Secretary of the Company (*Gieselman resigned effective December 12, 2016*);
- Salaries of \$55,000 (September 30, 2016 - \$30,000) were paid to Dr. Sazzad Hossain ("Dr. Hossain"), the Company's Chief Scientific Officer;
- Salaries of \$40,000 (September 30, 2016 - \$Nil) were paid to Alexandra Mancini ("Mancini"), the Company's Senior Vice President, Clinical & Regulatory Affairs (*Mancini was appointed effective October 31, 2016*); and
- Share-based payments are the fair value of options granted to key management personnel as described in Note 10.

**14. BASIC AND DILUTED LOSS PER SHARE**

Basic loss per share amounts are calculated by dividing the net loss for the period by the weighted average number of ordinary shares outstanding during the period.

	September 30 2017	September 30 2016
Loss attributable to shareholders	(\$1,820,154)	(\$418,016)
Weighted average number of common shares	130,905,079	72,178,172
Basic and diluted loss per share	(\$0.01)	(\$0.01)

**INMED PHARMACEUTICALS INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

**FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016**

**(Expressed in Canadian Dollars)**

---

**15. INCOME TAXES**

As at June 30, 2017, the Company has non-capital loss carry-forwards of approximately \$21,533,718 (June 30, 2016 - \$18,193,791) available to offset future taxable income in Canada. These non-capital loss carryforwards begin to expire in 2026.

The Company's tax position is calculated annually and readers are referred to the audited consolidated financial statements for the year ended June 30, 2017 for further details.

**16. SEGMENTED INFORMATION**

The Company operates in one segment, the biopharmaceutical research and development of novel, cannabinoid-based drug therapies.

**17. NON-CASH TRANSACTIONS**

Investing and financing activities that do not have a direct impact on cash flows are excluded from the statements of cash flows. During the period ended September 30, 2017 and September 30, 2016 the following transactions were excluded from the statements of cash flows:

- i) The issuance of 983,355 common shares pursuant to settlement of debt of \$108,169 in the three months ended September 30, 2016 (See Note 9);
- ii) The grant of Nil (September 30, 2016 – 28,000) Agents Warrants for recorded value of \$Nil (September 30, 2016 – \$527) – see Note 9; and
- iii) The purchase of equipment for \$22,628 (September 30, 2016 – \$Nil) where the purchase price was still payable at September 30, 2017.

**18. COMMITMENTS**

Pursuant to the terms of agreements with various contract research organizations, the Company is committed for contract research services at a cost of approximately \$288,307. In addition, pursuant to the terms of an agreement with a vendor, the Company is committed to purchase research materials at a cost of approximately \$57,516. All of these expenditures are expected to occur in fiscal 2018.

Pursuant to the terms of a May 31, 2017 Technology Assignment Agreement between the Company and the University of British Columbia ("UBC"), the Company is committed to pay royalties to UBC on certain licensing and royalty revenues received by the Company for biosynthesis of certain drug products that are covered by the agreement.

On June 22, 2017, the Company finalized an agreement to sublet office space with a sub-landlord. Under this agreement, the Company will be leasing 3,868 square feet at an annual cost of approximately \$77,500 plus operating costs. The term of the sublease is from September 1, 2017 to August 31, 2019.

Pursuant to the terms of an agreement with an employee, until July 10, 2019, if at any time its working capital is below \$750,000, the Company is committed to place into escrow \$125,000 to fund any potential severance amount due under that agreement.

## **19. CAPITAL MANAGEMENT**

The Company considers all components of shareholders' equity as capital. The Company's objectives when maintaining capital are to maintain sufficient capital base in order to meet its short-term obligations and at the same time preserve investor's confidence required to sustain future development of the business. The company is not exposed to any externally imposed capital requirements.

## **21. FINANCIAL RISK MANAGEMENT**

### **Market Risk**

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices are comprised of four types of risk: foreign currency risk, interest rate risk, commodity price risk and equity price risk. The Company does not currently have significant foreign exchange risk, commodity risk or equity price risk. In the future as the Company's expands its research and development activities outside of Canada there will be an increase in foreign exchange risk.

### **Interest Rate Risk:**

Interest rate risk is the risk that future cash flows will fluctuate as a result of changes in market interest rates. As at September 30, 2017, the Company held guaranteed investment certificates with face value of \$28,750 and the balance of its funds being held in cash. The Company's current policy is to invest excess cash in guaranteed investment certificates or interest bearing accounts of major Canadian chartered banks. The Company regularly monitors compliance to its cash management policy.

Cash is subject to floating interest rates.

The Company, as at September 30, 2017, does not have any borrowings. Interest rate risk is limited to potential decreases on the interest rate offered on cash and cash equivalents held with chartered Canadian financial institutions. The Company considers this risk to be immaterial.

### **Credit Risk:**

Credit risk is the risk of financial loss to the Company if a customer or a counter party to a financial instrument fails to meet its contractual obligations. Financial instruments which are potentially subject to credit risk for the Company consist primarily of cash. Cash is maintained with financial institutions of reputable credit and may be redeemed upon demand.

The carrying amount of financial assets represents the maximum credit exposure. Credit risk exposure is limited through maintaining cash with high-credit quality financial institutions and management considers this risk to be minimal for all cash assets based on changes that are reasonably possible at each reporting date.

**INMED PHARMACEUTICALS INC.**  
**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016**  
**(Expressed in Canadian Dollars)**

---

**Liquidity Risk:**

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company's policy is to ensure that it will always have sufficient cash to allow it to meet its liabilities when they become due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation. The key to success in managing liquidity is the degree of certainty in the cash flow projections. If future cash flows are fairly uncertain, the liquidity risk increases. As at September 30, 2017, the Company has cash and cash equivalents of \$6,032,762 (June 30, 2017 - \$6,707,796), current liabilities of \$189,551 (June 30, 2017 - \$369,674) and working capital surplus of \$6,003,813 (June 30, 2017 - \$6,574,847).